Arrowhead Pharmaceuticals price to book ratio ARWR

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 17.6×
10-year median: 10.1×
Against its 10-year history: 84th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.0× to 47.8×
Peer median: 9.2×

Arrowhead Pharmaceuticals' price to book ratio is 17.6× as of Oct 23, 2026.

That is above its ten-year median of 10.1×, higher than on 84% of days in the last ten years.

Over that time it ranged from 1.0× in Dec 2016 to 47.8× in Feb 2025.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

median 10.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.6×	13.6×	26.6×
2025	20.4×	3.1×	47.8×
2024	12.7×	5.7×	27.9×
2023	12.1×	6.9×	12.1×
2022	10.8×	6.8×	15.1×
2021	17.0×	14.2×	21.1×
2020	17.1×	5.3×	24.1×
2019	25.4×	8.6×	28.6×
2018	11.5×	4.5×	17.0×
2017	3.4×	1.2×	3.6×
2016	1.2×	1.0×	7.6×
2015	3.3×	2.1×	3.4×
2014	2.1×	1.7×	21.6×
2013	15.4×	3.0×	24.3×
2012	3.2×	2.5×	4.6×
2011	3.4×	2.6×	4.5×

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
ARWRArrowhead Pharmaceuticals	17.6×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
ALKSAlkermes plc.	4.0×
CORTCorcept Therapeutics	13.2×
AMRXAmneal Pharmaceuticals	197×
BMRNBiomarin Pharmaceutical	1.7×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
JAZZJazz Pharmaceuticals	2.9×
INDVIndivior Pharmaceuticals	n/m
Peer median	9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.